Research affirms imaging technique’s ability to characterise healthy and non-healthy tissue

Google+ Pinterest LinkedIn Tumblr +

In an article published in the Journal of Biomedical Optics (JBO), research observed across 92 ex vivo breast specimens suggests that there is little to no impact on the optical signatures of breast tissue after neoadjuvant chemotherapy.

The results of the study, in which diffuse reflectance spectroscopy (DRS) measurements were performed on 92 ex vivo breast specimens from 92 patients treated with and without neoadjuvant chemotherapy, show that contrast between healthy tissue and tumour tissue is not altered due to neoadjuvant chemotherapy – suggesting that the same reflectance spectral signatures can be used for tumour margin guidance independent of the chemotherapy status of the patient.

Because healthy and tumour tissue can be readily discriminated, tumour-margin assessment by DRS – which can discriminate different tissue types based on optical characteristics – becomes a feasible consideration during breast-conserving surgery, even if the patient has received neoadjuvant chemotherapy prior to surgery, a procedure that has become commonplace.

The ultimate goal of the intra-surgery application of DRS would allow the surgeon to assess the tissue while performing the resection of tumours to ensure that the resection margin is clear of tumour tissue.

According to JBO Editor-in-Chief, SPIE Fellow, and MacLean Professor of Engineering at the Thayer School of Engineering at Dartmouth College, New Hampshire, Brian W Pogue, the paper and its findings are notable due to the large number of clinical samples analysed, and the consequent relevance to assessing neoadjuvant chemotherapy changes.

“While a significant amount of work has been done defining the spectral signatures of breast cancer tumours and showing that this can be used for guidance, this is one of the first attempts to examine tumours following neoadjuvant chemotherapy as well. The results show that the signatures do not appear to change and so the status of the patient would not confound spectral imaging to help define the lumpectomy margin,” concluded Prof Pogue.


Source: International Society for Optics and Photonics (SPIE)

Share.

About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.